Windward Bio: Funding, Investors & Team (Sep 2026)
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programs for various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
Windward Bio has raised $165M across 1 funding round on record, the most recent a Series B of $165M announced in May 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Windward Bio Company Profile and Key Stats
Latest funding round on record: May 2026.
Windward Bio Funding Rounds
Windward Bio Founders and Leadership Team
Contact details for the Windward Bio team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Windward Bio Funding Compared to Other Biotechnology Startups
Windward Bio's latest round of $165M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Windward Bio in Biotechnology and Basel
Companies Similar to Windward Bio
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
Windward Bio Funding FAQs
What does Windward Bio do?
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programs for various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
How much funding has Windward Bio raised?
Windward Bio has raised $165M across 1 round on record. The most recent is a Series B of $165M announced in May 2026.
When did Windward Bio last raise funding?
Windward Bio's most recent funding round on record is a Series B of $165M, announced in May 2026.
Who founded Windward Bio?
FundedIQ lists Luca Santarelli (Founder) at Windward Bio.
Where is Windward Bio headquartered?
Windward Bio is based in Basel, Basel-Stadt, Switzerland.
How many employees does Windward Bio have?
Windward Bio is in the 11-50 employee band.
How does Windward Bio's funding compare to other Biotechnology startups?
Windward Bio's latest round of $165M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Windward Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Windward Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.